TRP-8802 demonstrated significant and prolonged improvement in primary endpoints for all five patients Across all patients treated with TRP-8802, daily binge eating episodes were reduced by an average ...
KELOWNA, BC / ACCESSWIRE / January 3, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing ...
KELOWNA, BC / ACCESSWIRE / January 26, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing ...
Deep-rooted psychological factors are often at the core of eating disorders, and psilocybin is increasingly showing promise. As treatment advances, Tryp Therapeutics developed psilocybin-based ...
KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics (TRYPF), Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on ...
Tryp Therapeutics, Inc. TRYPF TRYP has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its planned phase 2a clinical trial investigating the effects of ...
The TRYP by WyndhamTM select-service hotel brand announced the launch of a new global marketing and advertising campaign and the debut of the brand’s revamped consumer website – www.tryphotels.com – ...
Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder Beginning immediately following the post-dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results